Trial Profile

An Intrapatient Single Dose and Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of GBT021601, a Hemoglobin S Polymerization Inhibitor, in Participants With Sickle Cell Disease (SCD)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 May 2023 Status changed from active, no longer recruiting to completed.
13 Dec 2022 Pharmacodynamic Results from Phase 1 Studies assessing how PD biomarker data provides insight into the effectiveness and proof-of-concept data for GBT021601 presented at the 64th American Society of Hematology Annual Meeting and Exposition
10 Aug 2022 Planned End Date changed from 29 Mar 2022 to 31 Dec 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com